Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Therapeutics Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced third quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20 th Annual
View HTML
Toggle Summary Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study
SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) placed a partial
View HTML
Toggle Summary Mateon Therapeutics Reports Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced second quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics Reports First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced first quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a business update and announced 2017 financial results.  Business
View HTML
Toggle Summary Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it has completed a private placement transaction with
View HTML
Toggle Summary Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors
·  CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology
View HTML
Toggle Summary Mateon Therapeutics to Present at the 2018 Biotech Showcase
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it will present a company overview at the 2018 Biotech Showcase
View HTML
Toggle Summary Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapy Preliminary data suggest immuno-oncology applications for drug candidate   SOUTH SAN FRANCISCO, Calif. , Dec.
View HTML